(NASDAQ: SGP) Spyglass Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 23.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Spyglass Pharma's earnings in 2026 is -$39,869,000.On average, 6 Wall Street analysts forecast SGP's earnings for 2026 to be -$64,112,136, with the lowest SGP earnings forecast at -$76,981,361, and the highest SGP earnings forecast at -$41,766,483. On average, 5 Wall Street analysts forecast SGP's earnings for 2027 to be -$74,307,236, with the lowest SGP earnings forecast at -$99,911,979, and the highest SGP earnings forecast at -$51,383,303.
In 2028, SGP is forecast to generate -$80,103,401 in earnings, with the lowest earnings forecast at -$105,480,843 and the highest earnings forecast at -$50,821,737.